US5719147A
(en)
*
|
1992-06-29 |
1998-02-17 |
Merck & Co., Inc. |
Morpholine and thiomorpholine tachykinin receptor antagonists
|
KR100286412B1
(ko)
*
|
1993-12-29 |
2001-04-16 |
더블유. 지. 콜 |
치환된 모르폴린 유도체, 이의 제조방법 및 이를 포함하는 약제학적 조성물
|
IL112778A0
(en)
*
|
1994-03-04 |
1995-05-26 |
Merck & Co Inc |
Substituted heterocycles, their preparation and pharmaceutical compositions containing them
|
AU690682B2
(en)
*
|
1994-05-05 |
1998-04-30 |
Merck Sharp & Dohme Limited |
Morpholine derivatives and their use as antagonists of tachikinins
|
GB9505491D0
(en)
*
|
1995-03-18 |
1995-05-03 |
Merck Sharp & Dohme |
Therapeutic agents
|
GB9523244D0
(en)
*
|
1995-11-14 |
1996-01-17 |
Merck Sharp & Dohme |
Therapeutic agents
|
US6117855A
(en)
*
|
1996-10-07 |
2000-09-12 |
Merck Sharp & Dohme Ltd. |
Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
|
US5750549A
(en)
*
|
1996-10-15 |
1998-05-12 |
Merck & Co., Inc. |
Cycloalkyl tachykinin receptor antagonists
|
EP0942732B1
(de)
*
|
1996-12-02 |
2004-11-17 |
MERCK SHARP & DOHME LTD. |
Die verwendung von nk-1 rezeptor antagonisten für die behandlung von bewegungsstörungen
|
JP2001504851A
(ja)
*
|
1996-12-02 |
2001-04-10 |
メルク シヤープ エンド ドーム リミテツド |
性的機能不全の治療のためのnk−1受容体拮抗薬の使用
|
CA2273853A1
(en)
*
|
1996-12-02 |
1998-06-11 |
Merck Sharp & Dohme Limited |
Use of nk-1 receptor antagonists for treating cognitive disorders
|
US6114315A
(en)
*
|
1996-12-02 |
2000-09-05 |
Merck Sharp & Dohme Ltd. |
Use of NK-1 receptor antagonists for treating major depressive disorders with anxiety
|
US6100256A
(en)
*
|
1996-12-02 |
2000-08-08 |
Merck Sharp & Dohme Ltd. |
Use of NK-1 receptors antagonists for treating schizophrenic disorders
|
US5977104A
(en)
*
|
1996-12-02 |
1999-11-02 |
Merck Sharp & Dohme Ltd. |
Use of NK-1 receptor antagonists for treating bipolar disorders
|
JP2001504852A
(ja)
*
|
1996-12-02 |
2001-04-10 |
メルク シヤープ エンド ドーム リミテツド |
双極性障害の治療のためのnk−1受容体拮抗薬の使用
|
US6613765B1
(en)
*
|
1996-12-02 |
2003-09-02 |
Merck Sharp & Dohme Limited |
Use of NK-1 receptor antagonists for treating major depressive disorders
|
WO1998047513A1
(en)
*
|
1997-04-24 |
1998-10-29 |
Merck Sharp & Dohme Limited |
Use of nk-1 receptor antagonists for treating eating disorders
|
GB9716457D0
(en)
*
|
1997-08-04 |
1997-10-08 |
Merck Sharp & Dohme |
Therapeutic agents
|
GB9716463D0
(en)
*
|
1997-08-04 |
1997-10-08 |
Merck Sharp & Dohme |
Therapeutic agents
|
CA2298779A1
(en)
*
|
1997-08-04 |
1999-02-18 |
Merck Sharp & Dohme Limited |
Use of nk-1 receptor antagonists for treating aggressive behaviour disorders
|
CA2298777A1
(en)
*
|
1997-08-04 |
1999-02-18 |
Merck Sharp & Dohme Limited |
Use of nk-1 receptor antagonists for treating mania
|
US6087348A
(en)
*
|
1997-12-01 |
2000-07-11 |
Merck Sharp & Dohme Ltd. |
Use of NK-1 receptor antagonists for treating stress disorders
|
GB9813025D0
(en)
*
|
1998-06-16 |
1998-08-12 |
Merck Sharp & Dohme |
Chemical synthesis
|
GB9816897D0
(en)
*
|
1998-08-04 |
1998-09-30 |
Merck Sharp & Dohme |
Therapeutic use
|
ES2359235T3
(es)
|
1999-02-24 |
2011-05-19 |
F. Hoffmann-La Roche Ag |
Derivados de 4-fenilpiridina y su empleo como antagonistas del receptor nk-1.
|
HUP0200124A3
(en)
|
1999-02-24 |
2004-03-01 |
Hoffmann La Roche |
Phenyl- and pyridinyl derivatives, process for their preparation and pharmaceutical compositions containing them
|
CA2364662C
(en)
|
1999-02-24 |
2009-10-20 |
F. Hoffmann-La Roche Ag |
3-phenylpyridine derivatives and their use as nk-1 receptor antagonists
|
US6291465B1
(en)
|
1999-03-09 |
2001-09-18 |
Hoffmann-La Roche Inc. |
Biphenyl derivatives
|
FR2792835B3
(fr)
*
|
1999-04-27 |
2001-05-25 |
Sanofi Sa |
Utilisation du saredutant pour la preparation de medicaments utiles dans le traitement ou la prevention de l'ensemble des troubles de l'humeur, des troubles de l'adaptation ou des troubles mixtes anxiete-depression
|
GB9923748D0
(en)
|
1999-10-07 |
1999-12-08 |
Glaxo Group Ltd |
Chemical compounds
|
USRE39921E1
(en)
|
1999-10-07 |
2007-11-13 |
Smithkline Beecham Corporation |
Chemical compounds
|
US6552025B1
(en)
*
|
1999-11-24 |
2003-04-22 |
Emory University |
Diimino-piperazine derivatives for use as modulators of cell regulation
|
ATE253561T1
(de)
*
|
1999-11-29 |
2003-11-15 |
Hoffmann La Roche |
2-(3,5-bis-trifluoromethyl-phenyl)-n-methyl-n-( - morpholin-4-yl-4-o-tolyl-pyridin-3-yl)- isobutyramid
|
US6452001B2
(en)
|
2000-05-25 |
2002-09-17 |
Hoffmann-La Roche Inc. |
Diazapane derivatives useful as antagonists of neurokinin 1 receptor and methods for their formation
|
US6482829B2
(en)
|
2000-06-08 |
2002-11-19 |
Hoffmann-La Roche Inc. |
Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor
|
RS50932B
(sr)
|
2000-07-14 |
2010-08-31 |
F. Hoffmann-La Roche Ag. |
N-oksidi kao prolekovi 4-fenil-piridinskih derivata koji su antagonisti nk1 receptora
|
TWI287003B
(en)
|
2000-07-24 |
2007-09-21 |
Hoffmann La Roche |
4-phenyl-pyridine derivatives
|
TWI259180B
(en)
|
2000-08-08 |
2006-08-01 |
Hoffmann La Roche |
4-Phenyl-pyridine derivatives
|
GB0025354D0
(en)
*
|
2000-10-17 |
2000-11-29 |
Glaxo Group Ltd |
Chemical compounds
|
YU39503A
(sh)
|
2000-11-22 |
2006-05-25 |
F. Hoffmann-La Roche Ag. |
Derivati pirimidina
|
US6642226B2
(en)
|
2001-02-06 |
2003-11-04 |
Hoffman-La Roche Inc. |
Substituted phenyl-piperidine methanone compounds
|
GB0108594D0
(en)
*
|
2001-04-05 |
2001-05-23 |
Glaxo Group Ltd |
Chemical compounds
|
US20030055026A1
(en)
*
|
2001-04-17 |
2003-03-20 |
Dey L.P. |
Formoterol/steroid bronchodilating compositions and methods of use thereof
|
US6667344B2
(en)
|
2001-04-17 |
2003-12-23 |
Dey, L.P. |
Bronchodilating compositions and methods
|
US6849624B2
(en)
|
2001-07-31 |
2005-02-01 |
Hoffmann-La Roche Inc. |
Aromatic and heteroaromatic substituted amides
|
US6638981B2
(en)
|
2001-08-17 |
2003-10-28 |
Epicept Corporation |
Topical compositions and methods for treating pain
|
MY130373A
(en)
*
|
2001-10-29 |
2007-06-29 |
Malesci Sas |
Linear basic compounds having nk-2 antagonist activity and formulations thereof
|
US6903129B2
(en)
*
|
2001-12-14 |
2005-06-07 |
Hoffman-La Roche Inc. |
D-proline prodrugs
|
GB0203020D0
(en)
*
|
2002-02-08 |
2002-03-27 |
Glaxo Group Ltd |
Chemical compounds
|
GB0203022D0
(en)
*
|
2002-02-08 |
2002-03-27 |
Glaxo Group Ltd |
Chemical compounds
|
AU2003244455A1
(en)
*
|
2002-02-08 |
2003-09-02 |
Glaxo Group Limited |
Piperidylcarboxamide derivatives and their use in the treatment of tachykinim-mediated diseases
|
AR039625A1
(es)
*
|
2002-04-18 |
2005-03-02 |
Merck & Co Inc |
Proceso para la preparacion de 5-((2(r)--(1(r)- (3,5-bis (trifluormetil) fenil)etoxi-3 (s) - (4-fluorfenil) -4-morfolinil) metil) -1,2-dihidro-3h-1,2,4-triazol-3-ona
|
EP1556054A4
(de)
*
|
2002-05-29 |
2007-09-05 |
Univ California |
Antagonisierende nk1-rezeptoren hemmen den drogenmissbrauch
|
US20040023935A1
(en)
*
|
2002-08-02 |
2004-02-05 |
Dey, L.P. |
Inhalation compositions, methods of use thereof, and process for preparation of same
|
US20040109826A1
(en)
*
|
2002-12-06 |
2004-06-10 |
Dey, L.P. |
Stabilized albuterol compositions and method of preparation thereof
|
CN100562320C
(zh)
|
2003-01-31 |
2009-11-25 |
弗·哈夫曼-拉罗切有限公司 |
2-(3,5-二-三氟甲基-苯基)-N-[6-(1,1-二氧代-1λ6-硫代吗啉-4-基)-4-(4-氟-2-甲基-苯基)-吡啶-3-基]-N-甲基-异丁酰胺的新晶体变体
|
RU2347777C2
(ru)
|
2003-07-03 |
2009-02-27 |
Ф.Хоффманн-Ля Рош Аг |
Двойные агонисты nk1/nk3 для лечения шизофрении
|
TWI359675B
(en)
*
|
2003-07-10 |
2012-03-11 |
Dey L P |
Bronchodilating β-agonist compositions
|
US7288658B2
(en)
|
2003-07-15 |
2007-10-30 |
Hoffmann-La Roche Inc. |
Process for preparation of pyridine derivatives
|
WO2005033079A1
(ja)
*
|
2003-09-30 |
2005-04-14 |
Eisai Co., Ltd. |
ヘテロ環化合物を含有する新規な抗真菌剤
|
US20070020299A1
(en)
|
2003-12-31 |
2007-01-25 |
Pipkin James D |
Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
|
US20070020298A1
(en)
*
|
2003-12-31 |
2007-01-25 |
Pipkin James D |
Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
|
BRPI0418276B8
(pt)
|
2003-12-31 |
2021-05-25 |
Cydex Pharmaceuticals Inc |
formulação líquida inalável compreeendendo budesonida
|
ES2246687B2
(es)
|
2004-02-11 |
2006-11-16 |
Miguel Muñoz Saez |
Utilizacion de antagonistas no peptidicos de receptores nk1 para la produccion de apoptosis en celulas tumorales.
|
EP1730751B1
(de)
*
|
2004-03-12 |
2009-10-21 |
The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin |
Magnetoresistives medium
|
DK3520779T3
(da)
|
2004-04-23 |
2022-03-21 |
Cydex Pharmaceuticals Inc |
DPI formulering indeholdende sulfoalkylethercyclodextrin
|
MX2007000428A
(es)
|
2004-07-15 |
2008-03-05 |
Amr Technology Inc |
Tetrahidroisoquinolinas sustituidas con arilo y heteroarilo y uso de las mismas para bloquear la captacion de norepinefrina, dopamina y serotonina.
|
US20090227799A1
(en)
*
|
2004-08-09 |
2009-09-10 |
Kazutaka Nakamoto |
Novel Antimalarial Agent Containing Heterocyclic Compound
|
MX2007001713A
(es)
*
|
2004-08-11 |
2007-07-13 |
Donald L Barbeau |
Compuestos farmaceuticos no cardiotoxicos.
|
US7223737B1
(en)
|
2004-08-13 |
2007-05-29 |
Alcon, Inc. |
Method of treating dry eye disorders using glycosides
|
AR051475A1
(es)
*
|
2004-11-05 |
2007-01-17 |
Merck & Co Inc |
Procedimiento para acido{3- [2 (r) -[(1r) - 1-[ 3,5- bis( trifluorometil)- fenil] etoxi] -3 (s) - (4- fluorfenil) morfolin -4- il]metil -5-oxo-4,5-dihidro- [1,2,4]-triazol-1-il} fosfonico
|
ES2329827T3
(es)
|
2005-02-22 |
2009-12-01 |
F. Hoffmann-La Roche Ag |
Antagonistas de nk1.
|
US20100047338A1
(en)
|
2008-03-14 |
2010-02-25 |
Angela Brodie |
Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
|
RU2404969C2
(ru)
|
2005-03-23 |
2010-11-27 |
Ф. Хоффманн-Ля Рош Аг |
Метаболиты антагонистов nk-1 против рвоты
|
JP4874958B2
(ja)
*
|
2005-03-30 |
2012-02-15 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
ピリジン誘導体を含有する抗真菌剤
|
ES2382814T3
(es)
|
2005-05-17 |
2012-06-13 |
Merck Sharp & Dohme Ltd. |
Ácido cis-4-[(4-clorofenil)sulfonil]-4-(2,5-difluorofenil)ciclohexanopropanoico para el tratamiento del cáncer
|
ZA200800440B
(en)
|
2005-07-15 |
2009-12-30 |
Amr Technology Inc |
Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
|
EP1928427B1
(de)
|
2005-09-23 |
2009-12-30 |
F.Hoffmann-La Roche Ag |
Neue dosierformulierung
|
RU2008116844A
(ru)
|
2005-09-29 |
2009-11-10 |
Мерк энд Ко., Инк. (US) |
Ацилированные производные спиропиперидина как модуляторы рецептора меланокортина-4
|
EP1934204A2
(de)
*
|
2005-10-05 |
2008-06-25 |
Ranbaxy Laboratories, Ltd. |
Verfahren zur herstellung von aprepitant
|
US7629331B2
(en)
|
2005-10-26 |
2009-12-08 |
Cydex Pharmaceuticals, Inc. |
Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
|
TWI385169B
(zh)
|
2005-10-31 |
2013-02-11 |
Eisai R&D Man Co Ltd |
經雜環取代之吡啶衍生物及含有彼之抗真菌劑
|
US20070178049A1
(en)
*
|
2005-12-20 |
2007-08-02 |
Verus Pharmaceuticals, Inc. |
Systems and methods for the delivery of corticosteroids having an enhanced pharmacokinetic profile
|
US20070249572A1
(en)
*
|
2005-12-20 |
2007-10-25 |
Verus Pharmaceuticals, Inc. |
Systems and methods for the delivery of corticosteroids
|
US20070160542A1
(en)
*
|
2005-12-20 |
2007-07-12 |
Verus Pharmaceuticals, Inc. |
Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile
|
US20070197486A1
(en)
*
|
2005-12-20 |
2007-08-23 |
Verus Pharmaceuticals, Inc. |
Methods and systems for the delivery of corticosteroids
|
US20070185066A1
(en)
*
|
2005-12-20 |
2007-08-09 |
Verus Pharmaceuticals, Inc. |
Systems and methods for the delivery of corticosteroids
|
KR20080089659A
(ko)
*
|
2006-02-03 |
2008-10-07 |
그렌마크 파머수티칼스 엘티디. |
아프레피탄트의 비정질 및 결정 형태 및 그것의 제조 방법
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
US20070191323A1
(en)
*
|
2006-02-15 |
2007-08-16 |
Verus Pharmaceuticals, Inc. |
Stable corticosteroid mixtures
|
WO2008035726A1
(fr)
*
|
2006-09-21 |
2008-03-27 |
Eisai R & D Management Co., Ltd. |
Dérivé de pyridine substitué par un cycle hétéroaryle, et agent antifongique le comprenant
|
AU2007300627B2
(en)
|
2006-09-22 |
2012-02-16 |
Merck Sharp & Dohme Corp. |
Method of treatment using fatty acid synthesis inhibitors
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
GEP20115337B
(en)
|
2007-01-10 |
2011-11-25 |
St Di Ricerche Di Biologia Molecolare P Angeletti Spa |
Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
|
CN101641099A
(zh)
|
2007-01-24 |
2010-02-03 |
葛兰素集团有限公司 |
包含3,5-二氨基-6-(2,3-二氯苯基)-1,2,4-三嗪或r(-)-2,4-二氨基-5-(2,3-二氯苯基)-6-氟甲基嘧啶和nk1的药物组合物
|
AU2008233662B2
(en)
|
2007-04-02 |
2012-08-23 |
Msd K.K. |
Indoledione derivative
|
MX2009011051A
(es)
|
2007-04-20 |
2009-10-30 |
Hoffmann La Roche |
Derivados de pirrolidina como antagonistas del receptor nk1/nk3 doble.
|
CN101622251B
(zh)
*
|
2007-04-27 |
2012-07-04 |
卫材R&D管理有限公司 |
杂环取代吡啶衍生物的盐或其结晶
|
TW200841879A
(en)
*
|
2007-04-27 |
2008-11-01 |
Eisai R&D Man Co Ltd |
Pyridine derivatives substituted by heterocyclic ring and phosphonoamino group, and anti-fungal agent containing same
|
EP1994930A1
(de)
*
|
2007-05-22 |
2008-11-26 |
Novartis AG |
Triazol-Verbindungen zur Behandlung der Biofilm Bildung
|
EP3103791B1
(de)
|
2007-06-27 |
2018-01-31 |
Merck Sharp & Dohme Corp. |
4-carboxybenzylamino-derivate als histondeacetylase-hemmer
|
BRPI0815658A2
(pt)
|
2007-08-07 |
2015-02-18 |
Hoffmann La Roche |
Aril-éter pirrolidina como antagonistas do receptor nk3
|
US20090076007A1
(en)
*
|
2007-09-17 |
2009-03-19 |
Protia, Llc |
Deuterium-enriched aprepitant
|
US20090076008A1
(en)
*
|
2007-09-17 |
2009-03-19 |
Protia, Llc |
Deuterium-enriched fosaprepitant
|
US8513287B2
(en)
|
2007-12-27 |
2013-08-20 |
Eisai R&D Management Co., Ltd. |
Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
|
CA2716080C
(en)
|
2008-02-20 |
2016-12-13 |
Targia Pharmaceuticals |
Cns pharmaceutical compositions and methods of use
|
US8598184B2
(en)
|
2008-03-03 |
2013-12-03 |
Tiger Pharmatech |
Protein kinase inhibitors
|
US9156812B2
(en)
|
2008-06-04 |
2015-10-13 |
Bristol-Myers Squibb Company |
Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
|
US8623844B2
(en)
*
|
2008-07-17 |
2014-01-07 |
Navin Ganesh Bhatt |
Fosaprepitant dimeglumine intermediate, neutral fosaprepitant, and amorphous fosaprepitant dimeglumine and processes for their preparations
|
US8188119B2
(en)
*
|
2008-10-24 |
2012-05-29 |
Eisai R&D Management Co., Ltd |
Pyridine derivatives substituted with heterocyclic ring and γ-glutamylamino group, and antifungal agents containing same
|
CA2761389A1
(en)
|
2009-02-05 |
2010-08-12 |
Tokai Pharmaceuticals, Inc. |
Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
|
EP2409977A4
(de)
|
2009-03-17 |
2012-09-26 |
Daiichi Sankyo Co Ltd |
Amidderivat
|
US8691825B2
(en)
|
2009-04-01 |
2014-04-08 |
Merck Sharp & Dohme Corp. |
Inhibitors of AKT activity
|
JP2012526823A
(ja)
|
2009-05-12 |
2012-11-01 |
アルバニー モレキュラー リサーチ, インコーポレイテッド |
アリール、ヘテロアリール、および複素環置換テトラヒドロイソキノリンならびにそれらの使用
|
ES2528404T3
(es)
|
2009-05-12 |
2015-02-10 |
Bristol-Myers Squibb Company |
Formas cristalinas de (S)-7-([1,2,4]triazol[1,5-a]piridin-6-il)-4-(3,4-diclorofenil)-1,2,3,4-tetrahidroisoquinolina y sus usos
|
ES2662072T3
(es)
|
2009-05-12 |
2018-04-05 |
Albany Molecular Research, Inc. |
7-([1,2,4]triazolo[1,5-a]piridin-6-il)-4-(3,4-diclorofenil)-1,2,3,4-tetrahidroisoquinolina y uso de la misma
|
UY32799A
(es)
*
|
2009-07-24 |
2011-02-28 |
Novartis Ag |
Derivados de oxazina y su uso en el tratamiento de trastornos neurológicos
|
US8188079B2
(en)
*
|
2009-08-19 |
2012-05-29 |
Hoffman-La Roche Inc. |
3-amino-5-phenyl-5,6-dihydro-2H-[1,4]oxazines
|
UA109417C2
(uk)
|
2009-10-14 |
2015-08-25 |
Мерк Шарп Енд Доме Корп. |
ЗАМІЩЕНІ ПІПЕРИДИНИ, ЯКІ ПІДВИЩУЮТЬ АКТИВНІСТЬ p53, І ЇХ ЗАСТОСУВАННЯ
|
WO2011045817A2
(en)
*
|
2009-10-15 |
2011-04-21 |
Sandoz Private Limited |
Process for the preparation of fosaprepitant, intermediate and pharmaceutical acceptable salt thereof
|
WO2011120044A1
(en)
*
|
2010-03-26 |
2011-09-29 |
Duke University |
Conjugated neuroactive steroid compositions and methods of use
|
US8487102B2
(en)
|
2010-04-20 |
2013-07-16 |
Hoffmann-La Roche Inc. |
Pyrrazolopyridine compounds as dual NK1/NK3 receptor antagonists
|
US8999957B2
(en)
|
2010-06-24 |
2015-04-07 |
Merck Sharp & Dohme Corp. |
Heterocyclic compounds as ERK inhibitors
|
MY150939A
(en)
*
|
2010-07-13 |
2014-03-14 |
Novartis Ag |
Oxazine derivatives and their use in the treatment of neurological disorders
|
US9446029B2
(en)
|
2010-07-27 |
2016-09-20 |
Colorado State University Research Foundation |
Use of NK-1 receptor antagonists in management of visceral pain
|
AU2011285909B2
(en)
|
2010-08-02 |
2016-11-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
|
ES2376564B1
(es)
|
2010-08-12 |
2013-01-24 |
Manuel Vicente Salinas Martín |
Utilización de anticuerpos contra los receptores nk1, nk2 y/o nk3, para producir apoptosis en las células tumorales y modificar el estroma, la inmunidad y la vascularización intra y peritumorales, como tratamiento del cáncer.
|
RU2745848C2
(ru)
|
2010-08-17 |
2021-04-01 |
Сирна Терапьютикс, Инк. |
ОПОСРЕДУЕМОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНОВ ВИРУСА ГЕПАТИТА B (HBV) С ПРИМЕНЕНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК)
|
EP2608669B1
(de)
|
2010-08-23 |
2016-06-22 |
Merck Sharp & Dohme Corp. |
Neue pyrazolo-[1,5-a-]pyrimidinderivate als mtor-hemmer
|
EP2613782B1
(de)
|
2010-09-01 |
2016-11-02 |
Merck Sharp & Dohme Corp. |
Indazolderivate als erk-hemmer
|
EP2615916B1
(de)
|
2010-09-16 |
2017-01-04 |
Merck Sharp & Dohme Corp. |
Kondensierte pyrazolderivate als neue erk-hemmer
|
EP3327125B1
(de)
|
2010-10-29 |
2020-08-05 |
Sirna Therapeutics, Inc. |
Rna-interferenz-vermittelte inhibition von genexpression unter verwendung kurzer interferierender nukleinsäure (sina)
|
EP2654748B1
(de)
|
2010-12-21 |
2016-07-27 |
Merck Sharp & Dohme Corp. |
Indazolderivate als erk-hemmer
|
US8524897B2
(en)
|
2011-01-12 |
2013-09-03 |
Novartis Ag |
Crystalline oxazine derivative
|
PT2663561E
(pt)
|
2011-01-13 |
2016-06-07 |
Novartis Ag |
Derivados heterocíclicos novos e sua utilização no tratamento de distúrbios neurológicos
|
CN102127031B
(zh)
*
|
2011-01-17 |
2012-10-17 |
江苏江神药物化学有限公司 |
一种麻黄碱类化合物季胺盐及其合成方法和应用
|
US9067924B2
(en)
*
|
2011-03-04 |
2015-06-30 |
Hoffmann-La Roche Inc. |
1,4 thiazepines/sulfones as BACE1 and/or BACE2 inhibitors
|
FR2973031B1
(fr)
*
|
2011-03-23 |
2013-11-29 |
Univ Strasbourg |
Derives de l'allopregnanolone et de l'epiallopregnanolone et leurs utilisations pour traiter un etat neuropathologique
|
AU2012234682A1
(en)
*
|
2011-03-25 |
2013-10-10 |
Universite Laval |
Inhibitors of 17beta-HSD1, 17beta-HSD3 and 17beta-HSD10
|
CA2831730A1
(en)
|
2011-04-21 |
2012-10-26 |
Piramal Enterprises Limited |
A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
|
WO2012146692A1
(en)
|
2011-04-29 |
2012-11-01 |
Sandoz Ag |
Novel intermediates for the preparation of highly pure aprepitant or fosaprepitant
|
CA2837797A1
(en)
*
|
2011-06-07 |
2012-12-13 |
F. Hoffmann-La Roche Ag |
[1,3]oxazines
|
EP2729147B1
(de)
|
2011-07-04 |
2017-09-06 |
IRBM - Science Park S.p.A. |
Nk-1 rezeptorantagonisten zur behandlung der hornhautrevaskularisierung
|
CN102977142B
(zh)
*
|
2011-09-02 |
2017-03-29 |
江苏豪森药业集团有限公司 |
福沙匹坦二甲葡胺的制备方法
|
EP2770987B1
(de)
|
2011-10-27 |
2018-04-04 |
Merck Sharp & Dohme Corp. |
Neue verbindungen als erk-hemmer
|
WO2013087964A1
(es)
|
2011-12-13 |
2013-06-20 |
Servicio Andaluz De Salud |
Uso de agentes modificadores del ambiente peritumoral para el tratamiento del cáncer
|
US8338413B1
(en)
|
2012-03-07 |
2012-12-25 |
Novartis Ag |
Oxazine derivatives and their use in the treatment of neurological disorders
|
WO2013168176A2
(en)
*
|
2012-03-30 |
2013-11-14 |
Glenmark Generics Limited |
Process for preparation of fosaprepitant and salt thereof
|
CZ304982B6
(cs)
*
|
2012-04-30 |
2015-03-11 |
Zentiva, K.S. |
Způsob přípravy a čištění nových polymorfů intermediátu fosaprepitantu
|
EP3919620A1
(de)
|
2012-05-02 |
2021-12-08 |
Sirna Therapeutics, Inc. |
Zusammensetzungen mit kurzer interferierender nukleinsäure (sina)
|
CN102675369B
(zh)
*
|
2012-05-16 |
2017-07-11 |
北京华众思康医药技术有限公司 |
一种制备[3‑[(2r)‑[(1r)‑1‑[3,5‑二(三氟甲基)苯基]乙氧基]‑3(s)‑(4‑氟苯基)吗啉‑4‑基]甲基]‑5‑氧代‑4,5‑二氢‑[1,2,4]‑三唑‑1‑基]膦酸一苄酯的新方法
|
SG11201407397WA
(en)
*
|
2012-05-31 |
2014-12-30 |
Repros Therapeutics Inc |
Formulations and methods for vaginal delivery of antiprogestins
|
PT2866797T
(pt)
|
2012-07-06 |
2020-07-22 |
Pharmathen Sa |
Composição farmacêutica injetável estável do antagonista do recetor da neurocinina 1 e seu processo de preparação
|
JP6280554B2
(ja)
|
2012-09-28 |
2018-02-14 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
Erk阻害剤である新規化合物
|
CN104822693A
(zh)
*
|
2012-10-29 |
2015-08-05 |
阿勒根公司 |
比马前列素和前列腺酰胺的磷酸酯
|
US8778964B2
(en)
|
2012-11-05 |
2014-07-15 |
Bayer Pharma Aktiengesellschaft |
Hydroxy-substituted imidazo[1,2-a]-pyridinecarboxamides and their use
|
US9126998B2
(en)
|
2012-11-05 |
2015-09-08 |
Bayer Pharma AG |
Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
|
US8796305B2
(en)
|
2012-11-05 |
2014-08-05 |
Bayer Pharma Aktiengesellschaft |
Carboxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use
|
US9624214B2
(en)
|
2012-11-05 |
2017-04-18 |
Bayer Pharma Aktiengesellschaft |
Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
|
KR102161331B1
(ko)
|
2012-11-28 |
2020-09-29 |
머크 샤프 앤드 돔 코포레이션 |
암을 치료하기 위한 조성물 및 방법
|
ES2707305T3
(es)
|
2012-12-20 |
2019-04-03 |
Merck Sharp & Dohme |
Imidazopiridinas sustituidas como inhibidores de HDM2
|
EP2951180B1
(de)
|
2013-01-30 |
2018-05-02 |
Merck Sharp & Dohme Corp. |
2,6,7,8-substituierte purine als hdm2-inhibitoren
|
ES2493693B1
(es)
|
2013-02-11 |
2015-07-07 |
Servicio Andaluz De Salud |
Método para predecir o pronosticar la respuesta de un sujeto humano que padece un cáncer al tratamiento con un antagonista del receptor NK1
|
US20160009755A1
(en)
*
|
2013-03-01 |
2016-01-14 |
Revlon Consumer Products Corporation |
Cyrrhetinic alkyl esters and protected derivatives thereof
|
LT3461834T
(lt)
|
2013-03-13 |
2021-10-25 |
Sage Therapeutics, Inc. |
Neuroaktyvūs steroidai
|
AU2014236135A1
(en)
|
2013-03-14 |
2015-09-10 |
Thomas Jefferson University |
Androgen receptor down-regulating agents and uses thereof
|
AU2013386732B2
(en)
*
|
2013-04-18 |
2018-10-18 |
Xi'an Libang Pharmaceutical Technology Co., Ltd. |
Ester derivative of 7-alpha-[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17beta-diol having antitumour activity and preparation method thereof
|
WO2014195333A1
(de)
|
2013-06-04 |
2014-12-11 |
Bayer Pharma Aktiengesellschaft |
3-aryl-substituierte imidazo[1,2-a]pyridine und ihre verwendung
|
US9808472B2
(en)
|
2013-08-12 |
2017-11-07 |
Tokai Pharmaceuticals, Inc. |
Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
|
WO2015034925A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
JP6548641B2
(ja)
|
2013-10-28 |
2019-07-24 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
転移性前立腺癌の治療
|
CN104650142B
(zh)
*
|
2013-11-25 |
2018-06-22 |
山东新时代药业有限公司 |
一种福沙匹坦二甲葡胺的制备方法
|
CN103694146B
(zh)
*
|
2013-12-04 |
2015-10-28 |
深圳万乐药业有限公司 |
2-(2-氯-1-亚乙基)酰肼甲酸甲酯的制备方法
|
ES2541870B1
(es)
|
2013-12-27 |
2016-05-12 |
Servicio Andaluz De Salud |
Uso de antagonistas no peptídicos de NK1 en una determinada dosis para el tratamiento del cáncer
|
US20160324881A1
(en)
*
|
2013-12-30 |
2016-11-10 |
Oncoprevent Gmbh |
Neurokinin-1 Receptor Antagonists For Use In A Method Of Prevention Of Cancer
|
WO2015124544A1
(de)
|
2014-02-19 |
2015-08-27 |
Bayer Pharma Aktiengesellschaft |
3-(pyrimidin-2-yl)imidazo[1,2-a]pyridine
|
US9771360B2
(en)
|
2014-03-21 |
2017-09-26 |
Bayer Pharma Aktiengesellschaft |
Cyano-substituted imidazo[1,2-A]pyridinecarboxamides and their use
|
TW201613888A
(en)
|
2014-09-26 |
2016-04-16 |
Helsinn Healthcare Sa |
Crystalline forms of an NK-1 antagonist
|
CN107001361A
(zh)
|
2014-12-02 |
2017-08-01 |
拜耳医药股份有限公司 |
杂芳基取代的咪唑并[1,2‑a]吡啶及其用途
|
ES2884086T3
(es)
|
2015-07-06 |
2021-12-10 |
Sage Therapeutics Inc |
Oxisteroles y sus procedimientos de uso
|
US10610532B2
(en)
|
2015-08-03 |
2020-04-07 |
Leiutis Pharmaceuticals Pvt. Ltd. |
Liquid formulations of fosaprepitant
|
US10005803B2
(en)
|
2015-10-06 |
2018-06-26 |
Helsinn Healthcare Sa |
Crystalline forms of fosnetupitant
|
US9913853B2
(en)
|
2015-11-03 |
2018-03-13 |
Cipla Limited |
Stabilized liquid fosaprepitant formulations
|
EP3383829B1
(de)
|
2015-12-01 |
2020-10-21 |
Piramal Enterprises Limited |
Verfahren zur herstellung von fosaprepitantdimeglumin und zwischenprodukt davon
|
CN105837526B
(zh)
*
|
2016-01-22 |
2018-02-27 |
浙江工业大学 |
一种阿瑞吡坦重要合成中间体(2s,3r)‑4‑苄基‑3‑(4‑氟苯基)吗啉‑2‑醇的制备方法
|
CN114272249A
(zh)
|
2016-04-01 |
2022-04-05 |
萨奇治疗股份有限公司 |
氧甾醇及其使用方法
|
US10752653B2
(en)
|
2016-05-06 |
2020-08-25 |
Sage Therapeutics, Inc. |
Oxysterols and methods of use thereof
|
CN107353303B
(zh)
|
2016-05-09 |
2020-09-01 |
上海奥博生物医药技术有限公司 |
一种福沙匹坦磷酸酯中间体的制备方法
|
CA3025837C
(en)
|
2016-06-06 |
2024-02-13 |
Helsinn Healthcare Sa |
Physiologically balanced injectable formulations of fosnetupitant
|
WO2018009867A1
(en)
|
2016-07-07 |
2018-01-11 |
Sage Therapeutics, Inc. |
Oxysterols and methods of use thereof
|
JP7149266B2
(ja)
|
2016-09-30 |
2022-10-06 |
セージ セラピューティクス, インコーポレイテッド |
C7置換オキシステロールおよびnmdaモジュレーターとしての方法
|
IL266093B2
(en)
|
2016-10-18 |
2024-02-01 |
Sage Therapeutics Inc |
Oxysterols and methods of using them
|
KR102521573B1
(ko)
|
2016-10-18 |
2023-04-14 |
세이지 테라퓨틱스, 인크. |
옥시스테롤 및 그의 사용 방법
|
JP7271437B2
(ja)
|
2017-04-10 |
2023-05-11 |
チェイス セラピューティクス コーポレイション |
Nk1拮抗薬組み合わせおよびシヌクレイノパチーを治療する方法
|
US11266633B2
(en)
|
2017-06-30 |
2022-03-08 |
Chase Therapeutics Corporation |
NK-1 antagonist compositions and methods for use in treating depression
|
WO2019038656A1
(en)
|
2017-08-21 |
2019-02-28 |
Leiutis Pharmaceuticals Pvt, Ltd |
NEW TRIPLE COMBINATION FORMULATIONS FOR ANTIEMETIC THERAPY
|
CN109694390A
(zh)
*
|
2017-10-24 |
2019-04-30 |
齐鲁制药有限公司 |
一种福沙匹坦氮氧化物
|
WO2019094311A1
(en)
|
2017-11-08 |
2019-05-16 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
AU2019223237A1
(en)
*
|
2018-02-26 |
2020-09-03 |
Ospedale San Raffaele S.R.L. |
NK-1 antagonists for use in the treatment of ocular pain
|
US20210277009A1
(en)
|
2018-08-07 |
2021-09-09 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
US20210309688A1
(en)
|
2018-08-07 |
2021-10-07 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
WO2021180885A1
(en)
|
2020-03-11 |
2021-09-16 |
Ospedale San Raffaele S.R.L. |
Treatment of stem cell deficiency
|
CA3173697A1
(en)
|
2020-04-03 |
2021-10-07 |
Mike TROWER |
An nk-1 receptor antagonist for treating a disease selecting from sepsis, septic shock, acute respiratory distress syndrome (ards) or multiple organ dysfunction syndrome (mods)
|
JP2023531863A
(ja)
|
2020-06-02 |
2023-07-26 |
ネッレ セラピューティクス リミテッド |
肺の機械的損傷によって促進される肺線維症状態の治療で使用するためのニューロキニン(nk)-1受容体拮抗薬
|
JPWO2022107843A1
(de)
|
2020-11-19 |
2022-05-27 |
|
|
US11541066B2
(en)
|
2021-03-04 |
2023-01-03 |
Extrovis Ag |
Stable ready-to-use parenteral compositions of fosaprepitant
|
CN113582982B
(zh)
*
|
2021-06-15 |
2023-06-16 |
山东罗欣药业集团股份有限公司 |
一种nk1受体拮抗剂的制备方法
|